cagrilintide trial Once-weekly for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 HCPLive - CagriSema, a fixed
HCPLive CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss to placebo in adults with obesity or overweight and T2D in the Phase Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online cagrilintide Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network MetaAnalysis of Randomized Clinical Trials Hamarsheh 2026 Endocrinology, Diabetes & Metabolism Wiley
Pay in 4 interest-free payments of $6.61 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6


